查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2000407

仿生系統市場預測至2034年：按產品、器官類型、組件、材料、應用和地區分類的全球分析

Microphysiological Systems Market Forecasts to 2034 - Global Analysis By Product, By Organ Type, By Component, By Material, By Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球仿生系統（器官晶片）市場規模將達到 3.0761 億美元，並在預測期內以 35.2% 的複合年成長率成長，到 2034 年將達到 4.4833 億美元。

仿生系統（器官晶片）是一種先進的微流體裝置，它利用置於人工建造環境中的活細胞來複製人體器官的結構和功能。這些系統能夠模擬血液流動、機械力以及細胞間相互作用等生理條件，進而建構出肺、肝、心臟和大腦等器官的逼真模型。它們被廣泛應用於藥物研發、毒性測試和疾病建模。透過提供與人體相關的生物學訊息，器官晶片平台能夠減少對動物實驗的依賴，提高臨床前試驗的預測準確性，並加速藥物研發和個人化醫療的發展。

對先進藥物檢測的需求日益成長

傳統的動物模型和2D細胞培養往往無法複製人體生理反應，導致臨床試驗中藥物失敗率居高不下。器官晶片技術提供了一個微工程環境，能夠模擬人體器官的結構和功能。這使得研究人員能夠在臨床試驗前更好地評估藥物的毒性、療效和藥物動力學。製藥公司正擴大採用這些系統來降低研發成本並提高成功率。隨著製藥業致力於更安全、更快速的藥物研發，對先進測試平台的需求也持續成長。

缺乏標準化的檢驗通訊協定

晶片設計、細胞來源和調查方法在不同的研究機構和公司之間往往存在差異。這種缺乏統一標準的現狀使得不同實驗室之間的結果難以比較。監管機構在藥物核准過程中也要求提供一致的檢驗資料才能核准器官晶片系統。如果沒有全球認可的測試框架，製藥公司可能會猶豫是否將這些系統全面整合到其研發管線中。因此，監管方面的明確規定和標準化的指導方針對於器官晶片系統的廣泛市場應用至關重要。

與人工智慧驅動的藥物發現相結合

人工智慧技術能夠分析微生理系統產生的複雜生物數據，從而更準確地預測藥物反應。將人工智慧與晶片器官平台結合，可實現高通量篩檢並改善疾病機制的建模。這種方法使研究人員能夠更快地識別有前景的候選藥物，同時減少實驗誤差。人工智慧驅動的分析也有助於晶片設計和實驗參數的最佳化。隨著製藥公司擴大採用數位化和數據驅動的研究方法，人工智慧與晶片器官技術的協同效應有望加速創新。

與傳統細胞培養模型的競爭

傳統方法應用廣泛、成本低廉，且為所有實驗室的研究人員所熟知。許多製藥公司已經擁有圍繞2D和3D細胞培養系統的基礎設施和專業技術。過渡到器官晶片平台可能需要在設備和培訓方面進行額外投資。此外，一些早期研究應用可能仍然依賴更易於實施的簡單模型。這種對傳統模型的持續依賴可能會減緩微生理系統的應用普及。

新冠疫情的影響：

新冠疫情對仿生系統市場產生了複雜但最終的正面影響。疫情期間，研究人員尋求先進的模型來研究病毒感染並評估潛在的治療方法。器官晶片平台被用來模擬人類肺部和免疫系統對SARS-CoV-2的反應。這加速了人們對仿生技術的研究興趣和投資。然而，供應鏈中斷和實驗室的暫時關閉最初減緩了研究活動。資金籌措重點也轉向了與疫情相關的計劃。

在預測期內，肝臟晶片細分市場預計將佔據最大的市場佔有率。

肝臟在藥物代謝和毒性評估中發揮著至關重要的作用，因此，預計在預測期內，肝臟晶片將佔據最大的市場佔有率。製藥公司在藥物研發的早期階段就將肝毒性評估放在首位。肝臟晶片模型能夠忠實地模擬人類肝臟的超微結構和生化反應。與傳統的細胞培養相比，這些系統使研究人員能夠更精確地研究代謝交互作用和藥物的長期效應。臨床試驗中藥物性肝損傷的高發生率進一步推動了對可靠肝臟模型的需求。

在預測期內，個人化醫療領域預計將呈現最高的複合年成長率。

在預測期內，由於人們對以患者為中心的治療方案日益關注，因此個人化醫療領域預計將呈現最高的成長率。器官晶片平台能夠整合來自個別患者的細胞，從而更精確地模擬疾病狀態。這使得研究人員能夠評估不同患者對特定藥物和治療方法的反應。這種能力在癌症和神經系統疾病等複雜疾病中尤其重要。製藥公司和研究機構正加大對個人化療法研發的投入。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其強大的研究基礎設施和對生物醫學創新的巨額投資。該地區匯聚了許多主要企業、製藥公司和學術研究機構。政府機構和私人投資者正積極資助與先進藥物檢測技術相關的研究。此外，大學與產業界的合作正在加速器官晶片平台的技術進步。主要市場參與企業的加入也進一步推動了該地區的成長。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於藥物研發活動的增加和生技產業的擴張。中國、日本、韓國和印度等國家正在生命科學研究基礎建設進行大量投資。全球製藥公司與區域研究機構之間合作的加強也促進了市場擴張。該地區各國政府正透過資助計畫和生物技術相關措施支持創新。此外，對先進藥物檢測技術日益成長的需求也推動了器官晶片系統的應用。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

目錄

第1章：執行摘要

  • 市場概覽及主要亮點
  • 成長動力、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章 全球仿生系統市場：依產品分類

  • 單一器官晶片系統
  • 多重器官（晶片人體）系統
  • 疾病特異性晶片模型
  • 高通量篩檢平台
  • 整合器官晶片工作站
  • 模組化和可自訂的晶片平台
  • 其他產品

第6章 全球仿生系統市場：依器官類型分類

  • 肝片
  • 心形晶片
  • 肺晶片
  • 腎形片
  • 皮膚和屏障模型
  • 其他器官類型

第7章 全球仿生系統市場：依組件分類

  • 微流體晶片
  • 細胞株和類器官
  • 試劑和培養基
  • 泵浦和流量控制設備
  • 其他規則

第8章：全球仿生系統市場：依材料分類

  • PDMS
  • 熱塑性塑膠
  • 玻璃基晶片
  • 基於矽的平台
  • 水凝膠基質
  • 其他材料

第9章 全球仿生系統市場：依應用分類

  • 藥物發現與篩檢
  • 毒性測試
  • 疾病模型
  • 個人化醫療
  • 其他用途

第10章：全球仿生系統市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟、合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Emulate, Inc.
  • CN Bio Innovations Ltd.
  • MIMETAS BV
  • TissUse GmbH
  • InSphero AG
  • AxoSim, Inc.
  • Kirkstall Ltd.
  • Nortis Inc.
  • AlveoliX AG
  • Hesperos, Inc.
  • Cherry Biotech
  • Altis Biosystems
  • NETRI
  • Draper Laboratory
  • Organovo Holdings, Inc.
Product Code: SMRC34504

According to Stratistics MRC, the Global Microphysiological Systems (Organ-on-a-Chip) Market is accounted for $307.61 million in 2026 and is expected to reach $448.33 million by 2034 growing at a CAGR of 35.2% during the forecast period. Microphysiological Systems (Organ-on-a-Chip) are advanced microfluidic devices that replicate the structure and function of human organs using living cells arranged in engineered environments. These systems simulate physiological conditions such as blood flow, mechanical forces, and cellular interactions, enabling realistic models of organs like the lung, liver, heart, or brain. They are widely used in drug discovery, toxicity testing, and disease modeling. By providing human-relevant biological insights, organ-on-a-chip platforms reduce reliance on animal testing, improve predictive accuracy in preclinical studies, and accelerate pharmaceutical research and personalized medicine development.

Market Dynamics:

Driver:

Rising demand for advanced drug testing

Traditional animal models and 2D cell cultures often fail to replicate human physiological responses, leading to high drug failure rates during clinical trials. Organ-on-a-chip technologies provide microengineered environments that mimic the structure and function of human organs. This enables researchers to better evaluate drug toxicity, efficacy, and pharmacokinetics before clinical testing. Pharmaceutical companies are increasingly adopting these systems to reduce development costs and improve success rates. As the pharmaceutical industry focuses on safer and faster drug development, demand for advanced testing platforms continues to grow.

Restraint:

Lack of standardized validation protocols

Different research institutions and companies often use varied chip designs, cell sources, and testing methodologies. This lack of uniform standards makes it difficult to compare results across laboratories. Regulatory agencies also require consistent validation data before accepting organ-on-chip systems for drug approval processes. Without globally accepted testing frameworks, pharmaceutical companies may hesitate to fully integrate these systems into their pipelines. The need for regulatory clarity and standardized guidelines is therefore critical for widespread market adoption.

Opportunity:

Integration with AI-driven drug discovery

AI technologies can analyze complex biological data generated from microphysiological systems to predict drug responses more accurately. Combining AI with organ-on-chip platforms enables high-throughput screening and improved modeling of disease mechanisms. This approach helps researchers identify promising drug candidates faster while reducing experimental errors. AI-powered analytics can also optimize chip design and experimental parameters. As pharmaceutical companies increasingly adopt digital and data-driven research methods, the synergy between AI and organ-on-chip technology is expected to accelerate innovation.

Threat:

Competition from traditional cell culture models

Conventional methods are widely established, inexpensive, and familiar to researchers across laboratories. Many pharmaceutical companies already have infrastructure and expertise built around 2D and 3D cell culture systems. Transitioning to organ-on-chip platforms may require additional investment in equipment and training. Furthermore, some early-stage research applications may still rely on simpler models that are easier to implement. This ongoing reliance on conventional models may slow the widespread adoption of microphysiological systems.

Covid-19 Impact:

The COVID-19 pandemic had a mixed but overall positive impact on the Microphysiological Systems market. During the pandemic, researchers sought advanced models to study viral infections and evaluate potential therapeutics. Organ-on-chip platforms were used to replicate human lung and immune responses to SARS-CoV-2. This accelerated research interest and investment in microphysiological technologies. However, supply chain disruptions and temporary laboratory shutdowns initially slowed research activities. Funding priorities also shifted toward pandemic-related projects.

The liver-on-a-chip segment is expected to be the largest during the forecast period

The liver-on-a-chip segment is expected to account for the largest market share during the forecast period as the liver plays a crucial role in drug metabolism and toxicity assessment. Pharmaceutical companies prioritize evaluating hepatotoxicity early in the drug development process. Liver-on-chip models closely mimic human liver microarchitecture and biochemical responses. These systems allow researchers to study metabolic interactions and long-term drug effects more accurately than traditional cell cultures. The high incidence of drug-induced liver injury in clinical trials further drives demand for reliable liver models.

The personalized medicine segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the personalized medicine segment is predicted to witness the highest growth rate due to increasing interest in patient-specific treatment approaches. Organ-on-chip platforms can incorporate cells derived from individual patients to model disease conditions more precisely. This enables researchers to evaluate how different patients respond to specific drugs or therapies. Such capabilities are particularly valuable in complex diseases like cancer and neurological disorders. Pharmaceutical companies and research institutions are increasingly investing in personalized treatment development.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to strong research infrastructure and high investment in biomedical innovation. The region hosts many leading biotechnology firms, pharmaceutical companies, and academic research institutions. Government agencies and private investors actively fund research related to advanced drug testing technologies. Additionally, collaborations between universities and industry players accelerate technological advancements in organ-on-chip platforms. The presence of major market participants further strengthens regional growth.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by increasing pharmaceutical research activities and expanding biotechnology sectors. Countries such as China, Japan, South Korea, and India are investing heavily in life science research infrastructure. Growing collaborations between global pharmaceutical companies and regional research institutions also contribute to market expansion. Governments in the region are supporting innovation through funding programs and biotechnology initiatives. Additionally, the rising demand for advanced drug testing technologies is boosting adoption of organ-on-chip systems.

Key players in the market

Some of the key players in Microphysiological Systems (Organ-on-a-Chip) Market include Emulate, Inc., CN Bio Innovations Ltd., MIMETAS BV, TissUse GmbH, InSphero AG, AxoSim, Inc., Kirkstall Ltd., Nortis Inc., AlveoliX AG, Hesperos, Inc., Cherry Biotech, Altis Biosystems, NETRI, Draper Laboratory and Organovo Holdings, Inc.

Key Developments:

In June 2025, Emulate launched the AVA Emulation System, a high-throughput benchtop instrument that automates the culture, incubation, and real-time imaging of up to 96 independent Organ-Chip samples simultaneously. The system utilizes the new Chip-Array consumable and is designed to integrate with standard laboratory workflows, reducing consumable costs by four-fold and hands-on time by more than half compared to previous technologies.

In April 2025, CN Bio entered a long-term strategic partnership with Pharmaron to validate and integrate its PhysioMimix(R) OOC technology into Pharmaron's global R&D platform, focusing on disease modelling, toxicity testing, and ADME studies . The agreement includes the installation of PhysioMimix instruments at Pharmaron's global facilities to co-develop new applications addressing unmet needs in drug discovery.

Products Covered:

  • Single-Organ-on-a-Chip Systems
  • Multi-Organ (Body-on-a-Chip) Systems
  • Disease-Specific Chip Models
  • High-Throughput Screening Platforms
  • Integrated Organ-on-Chip Workstations
  • Modular & Customizable Chip Platforms
  • Other Products

Organ Types Covered:

  • Liver-on-a-Chip
  • Heart-on-a-Chip
  • Lung-on-a-Chip
  • Kidney-on-a-Chip
  • Skin & Barrier Models
  • Other Organ Types

Components Covered:

  • Microfluidic Chips
  • Cell Lines & Organoids
  • Reagents & Media
  • Pumps & Flow Controllers
  • Other Components

Materials Covered:

  • PDMS
  • Thermoplastics
  • Glass-Based Chips
  • Silicon-Based Platforms
  • Hydrogel Matrices
  • Other Materials

Applications Covered:

  • Drug Discovery & Screening
  • Toxicology Testing
  • Disease Modeling
  • Personalized Medicine
  • Other Applications

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Product

  • 5.1 Single-Organ-on-a-Chip Systems
  • 5.2 Multi-Organ (Body-on-a-Chip) Systems
  • 5.3 Disease-Specific Chip Models
  • 5.4 High-Throughput Screening Platforms
  • 5.5 Integrated Organ-on-Chip Workstations
  • 5.6 Modular & Customizable Chip Platforms
  • 5.7 Other Products

6 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Organ Type

  • 6.1 Liver-on-a-Chip
  • 6.2 Heart-on-a-Chip
  • 6.3 Lung-on-a-Chip
  • 6.4 Kidney-on-a-Chip
  • 6.5 Skin & Barrier Models
  • 6.6 Other Organ Types

7 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Component

  • 7.1 Microfluidic Chips
  • 7.2 Cell Lines & Organoids
  • 7.3 Reagents & Media
  • 7.4 Pumps & Flow Controllers
  • 7.5 Other Components

8 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Material

  • 8.1 PDMS
  • 8.2 Thermoplastics
  • 8.3 Glass-Based Chips
  • 8.4 Silicon-Based Platforms
  • 8.5 Hydrogel Matrices
  • 8.6 Other Materials

9 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Application

  • 9.1 Drug Discovery & Screening
  • 9.2 Toxicology Testing
  • 9.3 Disease Modeling
  • 9.4 Personalized Medicine
  • 9.5 Other Applications

10 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Emulate, Inc.
  • 13.2 CN Bio Innovations Ltd.
  • 13.3 MIMETAS BV
  • 13.4 TissUse GmbH
  • 13.5 InSphero AG
  • 13.6 AxoSim, Inc.
  • 13.7 Kirkstall Ltd.
  • 13.8 Nortis Inc.
  • 13.9 AlveoliX AG
  • 13.10 Hesperos, Inc.
  • 13.11 Cherry Biotech
  • 13.12 Altis Biosystems
  • 13.13 NETRI
  • 13.14 Draper Laboratory
  • 13.15 Organovo Holdings, Inc.

List of Tables

  • Table 1 Global Microphysiological Systems (Organ-on-a-Chip) Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Product (2023-2034) ($MN)
  • Table 3 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Single-Organ-on-a-Chip Systems (2023-2034) ($MN)
  • Table 4 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Multi-Organ (Body-on-a-Chip) Systems (2023-2034) ($MN)
  • Table 5 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Disease-Specific Chip Models (2023-2034) ($MN)
  • Table 6 Global Microphysiological Systems (Organ-on-a-Chip) Market, By High-Throughput Screening Platforms (2023-2034) ($MN)
  • Table 7 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Integrated Organ-on-Chip Workstations (2023-2034) ($MN)
  • Table 8 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Modular & Customizable Chip Platforms (2023-2034) ($MN)
  • Table 9 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Other Products (2023-2034) ($MN)
  • Table 10 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Organ Type (2023-2034) ($MN)
  • Table 11 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Liver-on-a-Chip (2023-2034) ($MN)
  • Table 12 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Heart-on-a-Chip (2023-2034) ($MN)
  • Table 13 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Lung-on-a-Chip (2023-2034) ($MN)
  • Table 14 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Kidney-on-a-Chip (2023-2034) ($MN)
  • Table 15 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Skin & Barrier Models (2023-2034) ($MN)
  • Table 16 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Other Organ Types (2023-2034) ($MN)
  • Table 17 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Component (2023-2034) ($MN)
  • Table 18 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Microfluidic Chips (2023-2034) ($MN)
  • Table 19 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Cell Lines & Organoids (2023-2034) ($MN)
  • Table 20 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Reagents & Media (2023-2034) ($MN)
  • Table 21 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Pumps & Flow Controllers (2023-2034) ($MN)
  • Table 22 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Other Components (2023-2034) ($MN)
  • Table 23 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Material (2023-2034) ($MN)
  • Table 24 Global Microphysiological Systems (Organ-on-a-Chip) Market, By PDMS (2023-2034) ($MN)
  • Table 25 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Thermoplastics (2023-2034) ($MN)
  • Table 26 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Glass-Based Chips (2023-2034) ($MN)
  • Table 27 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Silicon-Based Platforms (2023-2034) ($MN)
  • Table 28 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Hydrogel Matrices (2023-2034) ($MN)
  • Table 29 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Other Materials (2023-2034) ($MN)
  • Table 30 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Application (2023-2034) ($MN)
  • Table 31 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Drug Discovery & Screening (2023-2034) ($MN)
  • Table 32 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Toxicology Testing (2023-2034) ($MN)
  • Table 33 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Disease Modeling (2023-2034) ($MN)
  • Table 34 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Personalized Medicine (2023-2034) ($MN)
  • Table 35 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Other Applications (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.